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OBJECTIVES The study was conducted to determine if the capillary density of skeletal muscle is a potential
contributor to exercise intolerance in class II–III chronic heart failure (CHF).
BACKGROUND Previous studies suggest that abnormalities in skeletal muscle histology, contractile protein
content and enzymology contribute to exercise intolerance in CHF.
METHODS The present study examined skeletal muscle biopsies from 22 male patients with CHF
compared with 10 age-matched normal male control patients. Aerobic capacities, myosin
heavy chain (MHC) isoforms, enzymes, and capillary density were measured.
RESULTS The patients with CHF demonstrated a reduced peak oxygen consumption when compared
to controls (15.0 6 2.5 vs. 19.8 6 5.0 mlzkg21zmin21, p ,0.05). Using cell-specific
antibodies to directly assess vascular density, there was a reduction in capillary density in CHF
measured as the number of endothelial cells/fiber (1.42 6 0.28 vs. 1.74 6 0.35, p 5 0.02).
In CHF, capillary density was inversely related to maximal oxygen consumption (r 5 0.479,
p 5 0.02). The MHC IIx isoform was found to be higher in patients with CHF versus normal
subjects (28.5 6 13.6 vs. 19.5 6 9.4, p ,0.05).
CONCLUSIONS There was a significant reduction in microvascular density in patients with CHF compared
with the control group, without major differences in other usual histologic and biochemical
aerobic markers. The inverse relationship with peak oxygen consumption seen in the CHF
group suggests that a reduction in microvascular density of skeletal muscle may precede other
skeletal muscle alterations and play a critical role in the exercise intolerance characteristic of
patients with CHF. (J Am Coll Cardiol 1999;33:1956–63) © 1999 by the American College
of Cardiology
Exertional fatigue or exercise intolerance is a common
presenting symptom in over one-third of patients with
chronic heart failure (CHF). Although medical therapy has
reduced mortality, exercise intolerance remains a major
source of morbidity in this population. It is well accepted
that the severity of left ventricular systolic dysfunction, as
measured by left ventricular ejection fraction (LVEF) or
pulmonary capillary wedge pressure, cannot alone explain
the compromised functional capacity observed in chronic
heart failure (1–4). Left ventricular ejection fraction does
not correlate with exercise tolerance, and increases in
pulmonary capillary wedge pressure during exercise are not
responsible for exercise limitation in patients limited by
dyspnea. Therefore, although previously studied by many
groups, the complete mechanisms for exercise intolerance in
patients with CHF remain unknown.
Previous studies comparing class II–IV CHF patients to
active normals have demonstrated differences in exercise
tolerance accompanied by alterations in skeletal muscle
histology and biochemistry (5–9). These alterations include
a reduction of type I fibers, decreased aerobic enzymes and
contractile protein changes. Studies are conflicting regard-
ing changes in capillary density in the skeletal muscle of
CHF patients. Our laboratory (5) previously reported that
the number of capillaries per muscle fiber was decreased for
type I and type IIa fibers in CHF, but the ratio of capillaries
to cross-sectional fiber area was not different in CHF (due
to a concomitant reduction in fiber diameter) when com-
pared with normal subjects. On the basis of these findings,
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we concluded that overall oxygen diffusion distances were
unchanged in patients with CHF. Mancini et al. (8)
observed no difference in the number of capillaries per
muscle fiber, but did observe an increase in capillaries/mm2
cross-sectional area in CHF. Lipkin et al. (9) observed
capillaries per muscle fiber to be normal in CHF, whereas
Drexler et al. (7) found capillary length density (number of
capillaries per unit volume of muscle tissue) to be reduced in
CHF. Vascular density in these studies was assessed by
methods that detect components of the basement mem-
brane (i.e., periodic acid–Schiff staining), not by a direct
examination for endothelial cells. Therefore, capillary den-
sity warrants further investigation to explain the exercise
intolerance seen in patients with CHF.
The vascular bed in skeletal muscle functions mainly to
supply oxygen to muscle fibers. Capillary density strongly
correlates with human skeletal muscle oxidative capacity
(10,11). Therefore, it is also possible that it may be
important in determining exercise tolerance in CHF inde-
pendent of other biochemical or histological changes in the
skeletal muscle. The purpose of this investigation was to
determine if the capillary density of skeletal muscle is a
potential contributor to exercise intolerance in patients with
ambulatory class II–III CHF. We hypothesized that capil-
lary density in skeletal muscle of patients with CHF would
be reduced and positively correlated with measures of
exercise tolerance.
METHODS
Patient population. Twenty-two male patients (12 from
Duke Medical Center in Durham, North Carolina and 10
from Henry Ford Hospital in Detroit, Michigan) with class
II–III CHF due to left ventricular systolic dysfunction
(LVEF , 35%) and 10 (from Duke Medical Center)
age-matched male sedentary normals participated in the
study. All subjects with CHF were on a stable medical
regimen for a minimal of three months before the study.
Twenty were on digoxin, 21 were taking diuretics, 21
angiotensin-converting enzyme inhibitors, and 12 were
taking long-acting nitrates. All subjects with CHF were
symptom limited by dyspnea or leg fatigue. Thirteen pa-
tients had ischemic cardiomyopathy and nine had idiopathic
cardiomyopathy. All subjects were free of claudication, rales
and peripheral bruits. Exclusion criteria included insulin-
dependent diabetes mellitus, clinically significant chronic
obstructive pulmonary disease and peripheral vascular dis-
ease. All patients with CHF were sedentary and not
involved in any form of regular physical activity. There was
no indication of cardiopulmonary dysfunction in normal
subjects by either history or physical examination, and none
exhibited symptoms of ischemic heart disease. Normal
subjects were on no medications and none were engaged in
any type of regular aerobic exercise.
Study protocol. All studies were performed under research
protocols approved by the Institutional Review boards of the
Duke University, the Durham Veterans Administration
Medical Center and Henry Ford Hospital. Each subject was
informed of testing protocols and the potential risks and
benefits of participation. All subjects provided written
consent before participation.
Exercise testing. All patients with CHF underwent graded
upright bicycle exercise to a symptom-limited maximum on
a cycle ergometer (Fitron, Lumex, Ronkonkoma, New
York, or Monarck, Varberg, Sweden) with a 12-lead elec-
trocardiogram as previously described in our laboratory (5).
The workload began at 150 kpm/min and advanced in
3-min stages of 150 kpm/min. Equilibrium radionucleotide
angiograms were obtained for Duke University subjects at
rest using a low-energy mobile gamma camera. Expired
gases were analyzed continuously using a Sensormedics
4400 unit (Yorba Linda, California). Henry Ford patients
were included if LVEF was ,35% via equilibrium radio-
nucleotide angiograms or catheterization within six months,
or an echocardiogram showing LVEF ,30%.
Muscle biopsies. Biopsy samples were obtained from the
vastus lateralis using a modified Bergstrom needle technique
(12). Biopsy sites were anesthetized with a 2% lidocaine
solution, and 0.5-cm incisions were made through the skin
and fascia lata. The needle was consistently inserted to a
depth of 40 to 60 mm. Samples were then mounted in cross
section, in optimal cutting temperature (OCT) compound
(Miles Pharmaceutical, West Haven, Connecticut) beds,
and snap-frozen at 280°C.
Immunohistochemical analysis of vascular density. Vas-
cular density, expressed as endothelial cells/muscle fiber, was
determined by examining the total number of endothelial
cells relative to the total number of muscle fibers via light
microscopy. Endothelial cells were identified in histologic
sections using immunohistological techniques with an
endothelial-cell-specific monoclonal antibody in methods
previously described (13). Sections were cut throughout the
tissue block for analysis, ensuring a homogenous sample of
the block. Briefly, slides were allowed to come to room
temperature, placed in ice-cold acetone for 2 min and
phosphate buffered saline (PBS) for 5 min. Blocking solu-
tion (10% horse serum in PBS) was applied for 1 h at room
temperature. The primary antibody CD-31 (DACO) was
applied for 30 min at room temperature, followed by
sequential incubation with a biotinylated anti-mouse IgG
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and ABC reagent, according to the manufacturer’s specifi-
cations (Vectastain ABC kit, Vector Laboratories, Burlin-
game, California). Levamisole was added to block endoge-
nous alkaline phosphatase activity and immune complexes
were localized using the chromogenic alkaline phosphatase
substrate Vector Red (Vector Laboratories). When counter-
stained with hematoxolin, dehydrated and mounted with
Permount (Fisher Scientific) the antigen appears to be red
and the nuclei appears to be blue. A murine IgG monoclo-
nal antibody served as a negative control (13). A minimum
of six 2003 fields were counted. The mean number of fibers
counted for each sample was 40. Only fields that were in
cross section were counted. Fields not oriented in cross
section were excluded from analysis. A random number of
samples were chosen for a blinded repeat analysis. Intraob-
server variability on samples chosen for blind repeat analysis
was 5%. To exclude differences in cross-sectional area of
muscle fibers between CHF and normals, randomly selected
slides in cross section were projected and digitized. The
stained slide of human muscle was placed on the Olympus
1X70 microscope (Sterling, Virginia) and transferred onto a
computer screen at a magnification of 1003 through an
Optronics Engineering DEI-750 camera (Goleta, Califor-
nia) to the Adobe Premiere 4.2.1 program (San Jose,
California). Within this program the image of the muscle
fiber was captured and saved to the Adobe Photoshop LE
program, then opened into the NIH Image 1.6/ppc pro-
gram. In the NIH Image program the individual muscle
fiber was outlined and the total area was calculated.
Myosin heavy-chain analysis. Muscle biopsy samples
(;30 mg each) were minced with razor blades on a chilled
glass plate and transferred to microcentrifuge tubes. The
samples were washed and resuspended twice in a rigor
solution containing protease inhibitors (100 mmol/liter
NaCl; 15 mmol/liter Tris pH 8.0; 2 mmol/liter MgCl2; 4
mmol/liter EGTA; 7 mmol/liter B-mercaptoethanol,
PMSF, leupeptin, antipain and pepstatin). Following the
initial washes, the pellets were resuspended in rigor solution
containing 2% Triton X-100 (a detergent) to solubilize
membrane-bound components, and then washed two more
times in rigor buffer. Aliquots of myofibrils were dissolved
in a sodium dodecyl sulfate–polyacrylamide (SDS) gel-
loading buffer and frozen at 280°C.
Myosin heavy-chain (MHC) isoforms were resolved on
7.4% polyacrylamide gels containing 35% glycerol as de-
scribed by Talmadge et al. (14). Following electrophoresis,
gels were fixed in 15% acetic acid and stained with Coo-
massie Brilliant Blue G-250 (Bio-Rad, Hercules, Califor-
nia). The MHC isoforms I, IIa, and IIx were identified by
order of migration according to Ennion et al. (15) and
Smerdu et al. (16). Gels were scanned electronically, and
relative proportions of MHC isoform were measured using
NIH Image 1.60 for Macintosh and Jandel PeakFit for
Windows.
Enzymology. For the measurement of the maximal activ-
ities of several enzymes representative of different energy
pathways, frozen tissue samples were homogenized in a
phosphate buffer (pH 7.4) containing 0.02% bovine serum
albumin (BSA), 5 mmol/liter B-mercaptoethanol, and
0.05 mmol/liter EDTA and diluted (1:100) in 20 mmol/
liter imidazole buffer with 0.02% BSA (17).
Phosphofructokinase and succinic dehydrogenase activi-
ties were performed on the fresh homogenates while the
enzymes malate dehydrogenase, 3-hydoxyl-CoA dehydro-
genase, phosphorylase, hexokinase, and lactate dehydroge-
nase were performed on the frozen homogenates stored
(280°C) until the time of analysis. Enzyme assays were
performed fluorometrically using an end point assay at a
temperature of 23°C as outlined previously (17,18).
The maximal activity of one enzyme, cytochrome C
oxidase, was measured spectrophotometrically at 38°C
using a reaction medium that consisted of 970 ml of
10 mmol/liter potassium phosphate buffer (pH 7.0) and
20 ml of 1 mmol/liter solution of reduced cytochrome C
(Sigma C-2506 (St. Louis, Missouri)). The assay was
initiated by adding 10 ml of the sample (diluted 10:1 in
phosphate buffer) to the reaction medium (1 mmol/liter)
and the decrease in absorbance was measured at a
wavelength of 550 nm for 3 min. Maximum activity was
calculated using the measured slope and the extinction
coefficient of reduced cytochrome C at 550 nm.
Statistical analysis. Intergroup comparisons were per-
formed using the unpaired Student t test. Intragroup CHF
comparisons were made using the nonparametric Mann-
Whitney U test. A p value ,0.05 was considered significant.
To determine the relation of variables, Pearson correlations
were performed on linear regressions between the measured
biochemical and histologic markers and aerobic capacity.
For purposes of the analysis of relationships between aerobic
capacity and vascular density we divided the CHF patients
into three groups: those with a range in exercise capacity of
one metabolic equivalent (MET) surrounding the mean for
the entire group (4.25 METs) and those outside this range.
Thus, the groups analyzed were those with exercise capac-
ities ,4 METs, 4 to 5 METs, and .5 METs.
RESULTS
Table 1 contains demographic data for the CHF patients
and normal controls. There were no significant differences
in age, weight, height or body surface area (BSA)
between the two groups. Subjects with CHF had a peak
VO2 of 15.0 6 2.5 ml/kg/min versus 19.8 6 5.0 for
normals (p , 0.05) and a LVEF of 22.5 6 8.4% vs.
56.0 6 7.9 (p , 0.001).
Table 2 provides a summary of the relative content of
MHC type I, type IIa, and type IIx in the skeletal muscles
of individuals with CHF and normal subjects. Relative
percentages for MHC I and MHC IIa were all similar
between groups. The relative percentage of MHC IIx
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isoform was significantly higher in the CHF group
(patients with CHF 28.3 6 13.6% vs. normals 21.5 6
6.5%, p , 0.05).
Table 3 contains aerobic and glycolytic enzyme activities
in the two groups. One of four glycolytic enzymes mea-
sured, phosphorylase, was found to be elevated in CHF
(p ,0.05). Two out of five aerobic enzymes, 3-hydroxyl-
CoA dehydrogenase (p 5 0.001) and succinic dehydro-
genase (p , 0.05), were lower in patients with CHF.
Vascular density measurements for each of the individual
patients with CHF and normal subjects are shown in Figure
1. Overall, the number of endothelial cells/muscle fiber was
1.42 6 0.28 for patients with CHF versus 1.76 6 0.36 (p 5
0.02) in normals. There was no difference in fiber area
between the groups. Figure 2 illustrates capillaries/mm2 for
all subjects categorized by MET level. No differences were
detected in fiber diameter between groups.
Pearson correlation analysis was performed separately on
patients with CHF and on normal subjects to demonstrate
relationships between all markers of aerobic capacity and
peak VO2. No significant relationships were found in the
normal group. A significant inverse relationship was found
between maximal oxygen consumption and capillary density
and also between total exercise time and capillary density in
patients with CHF (Fig. 3).
DISCUSSION
The results of this study show that decreases in capillary
density may be partially responsible for exercise intolerance
in patients with mild to moderate CHF in the absence of
other major peripheral skeletal muscle alterations. Previous
studies comparing predominantly class III–IV patients with
CHF and healthy subjects with aerobic capacities .8
METs have clearly demonstrated that skeletal muscle alter-
ations in oxidative enzymes, fiber type, and contractile
proteins are partially responsible for early anaerobic metab-
olism and exercise intolerance. In this study, we found
differences in capillary density within subgroups of patients
with CHF (Fig. 2), and inverse relationships between
capillary density and two aerobic markers, maximal oxygen
consumption and total exercise time in patients with CHF
(Fig. 3). Taking into account previous studies in normal
subjects, these results were unexpected and counterintuitive.
On the basis of exercise training studies, we expected a
strong positive relationship between capillary density and
oxidative capacity. These results suggest that a maladaptive
process is active in the peripheral skeletal muscle in CHF.
Capillary density and aerobic capacity. The capillary bed
in skeletal muscle functions mainly to supply oxygen to
muscle fibers. Therefore, skeletal muscle capillary density
has a strong positive relationship with peak VO2 in normal
subjects. In humans, exercise training results in an increase
in the number of capillaries/muscle fiber and an increase in
the number of capillaries/mm2 of muscle (11). Interestingly,
in other animals, increases in capillary density precede
changes in the activity of oxidative enzymes and changes in
contractile protein composition in models of fiber type
transformation (19). Therefore, angiogenesis probably plays
a critical role in adaptive responses to functional demand,
where it correlates with improvements in endurance and
oxidative capacity (10,11,20).
The results of this study suggest that patients with CHF
and with severely compromised aerobic capacities may have
a compensatory, maladaptive angiogenic response to exer-
cise intolerance. In addition, we postulate that as CHF
worsens, capillary density changes may occur before major
enzyme or contractile protein changes. These two postulates
are supported by the weak but consistent trend that four of
five aerobic enzymes are decreased in patients with CHF
Table 2. Relative Content of Myosin Heavy Chain (%) in
Patients With Class II–III CHF and Normal Subjects
MHC I MHC IIa MHC IIx
CHF 36.9 6 14.6 34.7 6 9.6 28.3 6 13.6
Normal Subjects 41.0 6 8.6 37.5 6 10.3 21.5 6 6.5*
*Denotes p ,0.05.
Table 3. Skeletal Muscle Enzyme Activity in Patients With
Class II–III CHF and Normal Subjects (mol/kg protein/h)
Enzyme CHF Normal
Hexokinase 0.4 6 0.1 0.4 6 0.1
Lactate dehydrogenase 45.7 6 15.4 35.6 6 13.5
Phosphofructokinase 11.7 6 3.0 9.9 6 2.3
Phosphorylase 8.2 6 2.9 6.2 6 1.4*
Citrate synthetase 3.7 6 0.9 3.5 6 0.9
3-Hydroxyl-CoA dehydrogenase 2.8 6 1.2 3.8 6 0.6†
Malic dehydrogenase 5.7 6 1.7 6.1 6 2.6
Succinic dehydrogenase 2.4 6 0.8 3.1 6 0.8*
Cytochrome C oxidase 75.3 6 27.0 84.1 6 21.2
*Denotes p , 0.05. †Denotes p 5 0.001.
Table 1. Subject Demographic Data (Mean 6 SD)
Subject Age (yrs) BSA (m2) Weight (kg) Height (cm)
VO2max
(mlzkg21zmin21) LVEF (%)
CHF 60.5 6 10.9 2.0 6 0.2 87.5 6 16.5 175.6 6 7.5 15.0 6 2.5 22.5 6 8.4
Normals 61.1 6 6.6 2.0 6 0.2 84.1 6 12.5 176.7 6 10.2 19.8 6 5.0* 56.0 6 7.9†
*Denotes p ,0.05. †Denotes p ,0.001.
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compared with normals, and MHC IIx is greater in CHF
without a concomitant decrease in MHC I. Worsening
CHF may completely shift the enzyme panel toward a
significant decrease in all aerobic enzymes and a reduction
in MHC I compared to normal subjects.
Role of peripheral hemodynamics and metabolism. Al-
though it is known that patients with CHF have a reduced
blood flow to exercising skeletal muscle when compared to
normal subjects, several studies have demonstrated that anaer-
obic metabolism in skeletal muscle during exercise in patients
with CHF is not totally due to hypoperfusion (21–24). These
observations have been confirmed by 31P-NMR (nuclear
magnetic resonance) studies showing early anaerobic metabo-
lism in patients with CHF when compared with normals, even
with total occlusion of limb blood flow (25,26).
Furthermore, prior work from our laboratory demonstrated
that patients with CHF have the ability to optimally extract
oxygen from arteriole blood, as demonstrated by maximal
arteriovenous-oxygen differences (A-VO2) (2). This compensa-
tory response allows patients with CHF to obtain similar
oxygen uptakes at rest and submaximal workloads when
compared with normals. The increases seen in the capillary bed
cause an adjunctive increase in blood volume, thereby enhanc-
ing oxygen extraction. This study demonstrates that the num-
ber of fibers being subserved by capillaries is greater in CHF
muscle compared to normal muscle (the capillary-to-fiber ratio
is lower), but lower as the CHF group’s aerobic capacity
decreases. Therefore, there is a greater potential for maximiz-
ing oxygen removal in CHF. We postulate that a decreased
capillary density to the working muscles may contribute to
the earlier onset of skeletal muscle anaerobic metabolism in
ambulatory patients with class II–III CHF.
Interplay between cardiac output and skeletal muscle.
This study has identified reduced capillary density as a
possible contributor to exercise intolerance in patients with
CHF. This study also demonstrates that capillary density
can be altered independent of other major skeletal muscle
alterations. These findings do not exclude an interplay
between cardiac reserve and the periphery skeletal muscle.
One limitation of this study was that cardiac output was not
measured. Wilson et al. (27) have demonstrated that pa-
tients with CHF with normal cardiac output response to
exercise had skeletal muscle abnormalities. Interestingly,
this subgroup responded well to exercise training. Because
no study has thoroughly examined central hemodynamic
and peripheral alterations simultaneously or the feasibility of
reversing skeletal muscle alterations with a long-term exer-
cise program, it is difficult to ascertain the extent each is
contributing to the observed exercise intolerance. Decreased
cardiac reserve is a likely mechanism for early fatigue in
patients with CHF; however, identifying the peripheral
changes that occur, and their potential reversibility due to
deconditioning, would not only help solve the puzzle of
skeletal muscle pathophysiology in CHF compared to
deconditioned normal subjects, but also aid in therapeutic
interventions for all patients with CHF.
Figure 1. Comparison of endothelial cell/muscle fiber ratio (mean 6 SD) between patients with ambulatory class II–III CHF and normal
subjects (*p 5 0.02).
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Possible explanations for the inverse relationship be-
tween capillary density and aerobic capacity. Increased
capillary density for patients with low MET levels may
reflect the body’s attempt to maintain metabolic demands of
the periphery that are compromised as a result of an
abnormal cardiac output response to exercise. This may
explain the tiered levels of endothelial cell/muscle fiber seen
in CHF in Figure 2 and the inverse relationships illustrated
in Figure 3. These inverse relationships were not found in
the normal subjects (data not shown).
In addition, endothelial growth may also be stimulated by
an increased need to clear waste products, primarily lactate,
shown to accumulate in CHF. In subgroups of patients with
CHF, activities of daily living are performed at high
percentages of an individual’s maximal capacity, at or near
anaerobic threshold. It is possible that this represents an
exercise training stimulus for the skeletal muscle. For
example, home activities such as grocery shopping, food
preparation while standing, dish washing, simple lawn care
or light walking require MET levels of 2.5 to 3.5, equivalent
to 60% to 70% of maximal oxygen consumption in a patient
with a MET level of 4. This is well within a training range
to initiate a training response in skeletal muscle. Most of
patients with CHF in our study reported an independent
life that included a number of activities requiring 2.5 to 3.5
MET levels. In response to performing continuous bouts of
activity per day that are 60% to 70% of maximal oxidative
capacity, endothelial cell proliferation may occur in patients
with CHF that parallel exercise training at or above anaer-
obic threshold in normals.
Myosin heavy-chain isoforms and enzymes. Despite
finding significant differences in vascular density, we did not
observe markedly significant differences in two other tradi-
tional indicators of aerobic capacity, myosin heavy-chain
(MHC) isoforms and enzymatic profile. Although two of
five aerobic enzymes, 3-hydroxyl-CoA dehydrogenase and
succinic dehydrogenase, were found to be higher in normals
versus CHF patients, we do not believe this would account
for the difference in aerobic capacity. The MHC isoforms
show no relationship to oxygen consumption, but MHC IIx
in CHF patients is higher compared to normals.
Our previous study showed 3-hydroxyl-CoA dehydroge-
nase and succinic dehydrogenase to be different, and fiber
typing (comparable to MHC in the present study) to be
shifted more toward a glycolytic fiber type. Careful exami-
nation of other studies measuring capillary density reveals
similar findings. Drexler et al. (7) reported a reduced
capillary length density in CHF subjects with MET levels of
4.6, and Lipkin et al. (9) reported normal values for CHF
patients with MET levels of 3.3. These three studies, along
with the present study, demonstrate a potential inverse
relationship between capillary density and aerobic capacities
,4 METs.
Sensitivity of CD-31. The recognition of the importance
of vascularity to tumor growth (metastasis) has led to the
development of cell-specific monoclonal antibodies that can
Figure 2. Comparison of endothelial cell/muscle fiber ratio (mean 6 SD) between all subjects categorized by MET level (*p , 0.05 vs.
CHF 4–5 METs and p 5 0.01 vs. CHF .5 METs; **p 5 0.01 vs. CHF .5 METs; ***p ,0.05 vs. CHF .5 METs).
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be used to directly identify endothelial cells in histologic
sections. Even among cell-specific antibodies, antigen hetero-
geneity is an important feature, and CD-31 is regarded as the
most sensitive and specific marker for endothelial cells. Using
immunohistochemical techniques, Wlinder et al. (28) reported
that microvascular density in tumors was correlated with a
decrease in survival. Horak et al. (29) likewise used immuno-
histochemical techniques and cell-specific monoclonal anti-
bodies to demonstrate that neovascularization in a tumor was
associated with a decreased survival in patients. In their study,
CD-31 was more sensitive than von Willebrand factor in the
quantification of vascular density. Tenaglia and colleagues (30)
recently reported that the presence of neovascularization, as
demonstrated by CD-31 (not von Willebrand factor) immu-
nostaining, in coronary atherectomy samples was associated
with unstable coronary syndromes. Our study is the first to
report vascular density in human skeletal muscle utilizing
endothelial cell-specific monoclonal antibodies.
Conclusions. This is the first study that has attempted to
compare extremely sedentary normal subjects (MET ,6) to
mild to moderate class II–III CHF patients. The results of
the present study provide a possible explanation for leg
fatigue, one of the hallmark symptoms of exercise intoler-
ance in patients with ambulatory class II–III CHF. The
results also suggest substrate delivery to skeletal muscle can
be impaired at the microvascular level (i.e., capillary density)
without other major concomitant intrinsic abnormalities in
skeletal muscle. We postulate that within groups of CHF
patients there may be a discordant change in capillary
density that is inversely related to aerobic capacity. The
stimulus for this proposed angiogenesis remains unknown.
This study does not exclude the possibility that an attenu-
ated cardiac reserve may be primarily responsible for exercise
intolerance in CHF and supports the need for longitudinal
studies that simultaneously examine how cardiac output and
skeletal muscle changes affect aerobic capacity in compen-
satory CHF patients.
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